Capital Securities released a research report on April 14 stating that it maintains Kain Technology (688687.SH) purchase rating. The main reasons for the rating include: 1) Kailiwei's revenue and profitability continue to increase, and Kim Shu-hee still has room for growth in the long term; 2) R&D of innovative drugs is progressing steadily, and long-term interferons are being implemented soon. (Mainichi Keizai Shimbun)
首创证券4月14日发布研报称，维持凯因科技（688687.SH）买入评级。评级理由主要包括：1）凯力唯收入和盈利能力持续提升，金舒喜长期仍有增长空间；2）创新药研发稳步推进，长效干扰素兑现在即。（每日经济新闻）
Capital Securities released a research report on April 14 stating that it maintains Kain Technology (688687.SH) purchase rating. The main reasons for the rating include: 1) Kailiwei's revenue and profitability continue to increase, and Kim Shu-hee still h
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.